ES2155447T3 - Aplicaciones farmaceuticas de peptidos-iones metalicos. - Google Patents

Aplicaciones farmaceuticas de peptidos-iones metalicos.

Info

Publication number
ES2155447T3
ES2155447T3 ES93902846T ES93902846T ES2155447T3 ES 2155447 T3 ES2155447 T3 ES 2155447T3 ES 93902846 T ES93902846 T ES 93902846T ES 93902846 T ES93902846 T ES 93902846T ES 2155447 T3 ES2155447 T3 ES 2155447T3
Authority
ES
Spain
Prior art keywords
useful metal
medically useful
ions
peptides
pharmaceutical applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93902846T
Other languages
English (en)
Inventor
Buck A Rhodes
Paul O Zamora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhomed Inc
Original Assignee
Rhomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27542230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2155447(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/816,476 external-priority patent/US5346687A/en
Priority claimed from US07/816,477 external-priority patent/US5460785A/en
Priority claimed from US07/840,077 external-priority patent/US5443816A/en
Priority claimed from US07/998,820 external-priority patent/US5738838A/en
Priority claimed from US07/998,910 external-priority patent/US5556609A/en
Application filed by Rhomed Inc filed Critical Rhomed Inc
Application granted granted Critical
Publication of ES2155447T3 publication Critical patent/ES2155447T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

PEPTIDOS CONTENIENDO UN CAMPO DE FUNCION BIOLOGICA Y UN CAMPO DE FIJACION DE IONES METALICOS MEDICAMENTE UTILES, Y PROTEINAS CONTENIENDO ENLACES DE MONOSULFUROS O BISULFUROS, SE CLASIFICAN CON IONES METALICOS MEDICAMENTE UTILES PARA SU UTILIZACION USO EN LA DIAGNOSIS Y EL TRATAMIENTO DE UNA VARIEDAD DE ESTADOS PATOLOGICOS. LOS PEPTIDOS TIENEN LA SECUENCIA AMINOACIDA (R1) CONTENIENDO OPCIONALMENTE LA SECUENCIA IKVAV E YIGSR. EL CAMPO DE FIJACION DE IONES METALICOS MEDICAMENTE UTIL ES [Y1)N, [Y1 PARA CLASIFICAR LAS PROTEINAS CON IONES METALICOS MEDICAMENTE UTILES.
ES93902846T 1992-01-03 1992-12-31 Aplicaciones farmaceuticas de peptidos-iones metalicos. Expired - Lifetime ES2155447T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US07/816,476 US5346687A (en) 1989-08-09 1992-01-03 Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging
US07/816,477 US5460785A (en) 1989-08-09 1992-01-03 Direct labeling of antibodies and other protein with metal ions
US07/840,077 US5443816A (en) 1990-08-08 1992-02-20 Peptide-metal ion pharmaceutical preparation and method
US07/998,820 US5738838A (en) 1992-02-20 1992-12-30 IKVAV peptide radiopharmaceutical applications
US07/998,910 US5556609A (en) 1992-02-20 1992-12-30 YIGSR peptide radiopharmaceutical applications
PCT/US1992/011334 WO1993012819A1 (en) 1992-01-03 1992-12-31 Protein- and peptide-metal ion pharmaceutical applications

Publications (1)

Publication Number Publication Date
ES2155447T3 true ES2155447T3 (es) 2001-05-16

Family

ID=27542230

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93902846T Expired - Lifetime ES2155447T3 (es) 1992-01-03 1992-12-31 Aplicaciones farmaceuticas de peptidos-iones metalicos.

Country Status (8)

Country Link
EP (1) EP0629133B1 (es)
AT (1) ATE197767T1 (es)
AU (1) AU683833B2 (es)
CA (1) CA2127284C (es)
DE (1) DE69231586T2 (es)
DK (1) DK0629133T3 (es)
ES (1) ES2155447T3 (es)
WO (1) WO1993012819A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
US5443815A (en) * 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5783170A (en) * 1991-11-27 1998-07-21 Diatide, Inc. Peptide-metal chelate conjugates
US5738838A (en) * 1992-02-20 1998-04-14 Rhomed Incorporated IKVAV peptide radiopharmaceutical applications
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5620675A (en) * 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US6017512A (en) * 1992-06-23 2000-01-25 Diatide, Inc. Radiolabeled peptides
US5440015A (en) * 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
DE4301871A1 (de) * 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
DE69426673T2 (de) * 1993-06-23 2001-09-20 Diatide Inc Radiomarkierte somatostatin derivate zur abbildung und zur therapeutischen verwendung
DE69529988T2 (de) * 1994-05-02 2003-12-11 Diatide Inc Technetium-99m markierte bildformungsmittel
US6051206A (en) * 1994-06-03 2000-04-18 Diatide, Inc Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses
DE4425778A1 (de) * 1994-07-13 1996-01-18 Diagnostikforschung Inst Komplexverbindungen zur Diagnose von Gefäßerkrankungen
US5662885A (en) * 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
WO1996040289A1 (en) * 1995-06-07 1996-12-19 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US6027711A (en) * 1995-06-07 2000-02-22 Rhomed Incorporated Structurally determined metallo-constructs and applications
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
NZ505174A (en) 1996-05-15 2002-03-01 Altarex Inc Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer
US6106804A (en) * 1997-06-13 2000-08-22 The University Of New Mexico Arsenic-72 labeled compounds for tissue specific medical imaging
US7060251B1 (en) 1997-09-08 2006-06-13 The General Hospital Corporation Imaging agents for early detection and monitoring of cardiovascular plaque
EP1011738A1 (en) * 1997-09-08 2000-06-28 The General Hospital Corporation Imaging agents for early detection of cardiovascular plaque
JP4199420B2 (ja) * 1998-05-15 2008-12-17 ジーイー・ヘルスケア・リミテッド 標識化グルタミンおよびリジンアナログ
US6254852B1 (en) 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
US6685914B1 (en) 1999-09-13 2004-02-03 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
PL207834B1 (pl) * 2001-07-10 2011-02-28 Ge Healthcare As Związki na bazie peptydów, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna
EP1411987A2 (en) * 2001-07-31 2004-04-28 Immunomedics, Inc. Targeted polymeric delivery systems
US7317104B2 (en) 2003-06-13 2008-01-08 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7319149B2 (en) 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7371364B2 (en) 2003-08-15 2008-05-13 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
WO2005084168A2 (en) 2003-09-08 2005-09-15 Proportional Technologies, Inc. MINIATURIZED 62Zn/62Cu GENERATOR FOR HIGH CONCENTRATION CLINICAL DELIVERY OF 62Cu KIT FORMULATION FOR THE FACILE PREPARATION OF RADIOLABELED Cu-BIS(THIOSEMICARBAZONE) COMPOUNDS
EP1729823B1 (en) 2004-03-04 2009-11-04 GE Healthcare AS Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy
WO2007001339A2 (en) 2004-08-17 2007-01-04 Wake Forest University Health Sciences Ambient stored blood plasma expanders
US8920827B2 (en) 2005-10-21 2014-12-30 Wake Forest University Health Sciences Keratin bioceramic compositions
WO2007095151A2 (en) 2006-02-10 2007-08-23 Wake Forest University Health Sciences Nerve regeneration employing keratin biomaterials
WO2007098053A2 (en) 2006-02-17 2007-08-30 Wake Forest University Health Sciences Coatings and biomedical implants formed from keratin biomaterials
US8273702B2 (en) 2006-02-17 2012-09-25 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
US7909888B2 (en) 2008-12-19 2011-03-22 L'oreal Process for dyeing or lightening human keratin fibers using an anhydrous composition and a monoethanolamine/basic amino acid mixture, and suitable device therefor
EP2198843B1 (fr) 2008-12-19 2017-09-13 L'Oréal Eclaircissement de fibres kératiniques humaines mettant en oeuvre une composition anhydre comprenant un melange monoethanolamine / acide amine basique et dispositif
FR2940103B1 (fr) 2008-12-19 2011-06-10 Oreal Procede de coloration eclaircissante de matieres keratiniques mettant en oeuvre une emulsion comprenant un colorant et un agent alcalin et une composition oxydante
FR2940077B1 (fr) 2008-12-19 2012-07-20 Oreal Procede de coloration eclaircissante de matieres keratiniques mettant en oeuvre une composition anhydre colorante comprenant un agent alcalin et une composition oxydante.
JP5815205B2 (ja) 2008-12-19 2015-11-17 ロレアル 有機アミン及び無機塩基の存在下で、淡色化し、あるいは淡色化直接染色し、あるいは酸化染色する方法、及びそのためのデバイス
BRPI0907287B1 (pt) 2008-12-19 2018-01-02 L'oréal "processo de clareamento ou de coloração das fibras queratínicas e dispositivo com vários comportamentos"
JP5808077B2 (ja) 2008-12-19 2015-11-10 ロレアル 無機塩基の存在下で着色または明色化する方法及びキット
US7918902B2 (en) 2008-12-19 2011-04-05 L'oreal S.A. Process for lightening or process for direct dyeing or oxidation dyeing of keratin fibers in the presence of at least one ammonium salt and device therefor
WO2010093882A1 (en) 2009-02-13 2010-08-19 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
FR2942704B1 (fr) 2009-03-04 2011-09-02 Oreal Dispositif de distribution d'une composition tinctoriale pour les fibres keratiniques et procede associe.
FR2949971B1 (fr) 2009-09-17 2012-08-17 Oreal Procede d'eclaircissement ou de coloration en presence d'une composition anhydre particuliere et dispositif
FR2951080B1 (fr) 2009-10-13 2012-01-20 Oreal Composition comprenant un corps gras et un acide organophosphonique ou l'un de ses sels, procede de coloration ou d'eclaircissement la mettant en oeuvre et dispositifs
FR2954121B1 (fr) 2009-12-22 2016-03-25 Oreal Agent de coloration et/ou de decoloration des fibres keratiniques en deux parties, comprenant un corps gras particulier et une reductone.
FR2954101B1 (fr) 2009-12-22 2012-05-11 Oreal Agent de coloration et/ou de decoloration des fibres keratiniques en deux parties ou plus, comprenant une composition alcaline en emulsion inverse.
FR2954160B1 (fr) 2009-12-22 2012-03-30 Oreal Composition de coloration ou d'eclaircissement comprenant un corps gras et un polymere amphotere
FR2954127B1 (fr) 2009-12-22 2015-10-30 Oreal Agent de coloration et/ou de decoloration des fibres keratiniques en deux parties, comprenant un corps gras et un agent sequestrant.
WO2011076646A2 (en) 2009-12-22 2011-06-30 L'oreal Agent for dyeing and/or bleaching keratin fibres, comprising an inverse emulsion comprising an oxidizing agent
WO2011076647A2 (en) 2009-12-22 2011-06-30 L'oreal Inverse emulsion for treating the hair comprising a particular fatty substance and an alkaline agent
FR2954113B1 (fr) 2009-12-22 2013-03-08 Oreal Agent de coloration et/ou de decoloration des fibres keratiniques en deux parties ou plus, sous forme d'emulsion.
FR2954161B1 (fr) 2009-12-23 2012-03-02 Oreal Procede de coloration ou d'eclaircissement de fibres keratiniques en presence d'alcane(s) lineaire(s) volatil(s) et dispositif
JP2013521313A (ja) 2010-03-05 2013-06-10 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 制御送達系
US8545893B2 (en) 2010-03-08 2013-10-01 Wake Forest University Health Sciences Keratin biomaterials for treatment of ischemia
FR2958161B1 (fr) 2010-04-02 2012-04-27 Oreal Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une emulsion directe contenant un agent alcalin
FR2959127B1 (fr) 2010-04-22 2016-01-01 Oreal Emulsion inverse pour le traitement des cheveux comprenant un solvant particulier
FR2960773B1 (fr) 2010-06-03 2015-12-11 Oreal Procedes de traitement cosmetique utilisant un revetement a base d'un polymere polyamide-polyether
CA2818166C (en) 2010-11-17 2019-04-30 Wake Forest University Health Sciences Keratin compositions for treatment of bone deficiency or injury
US20140037626A1 (en) * 2012-07-18 2014-02-06 Echogen, Inc. Metal Abstraction Peptide With Release of Metal

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO167124C (no) * 1985-04-03 1991-10-09 Du Pont Merck Pharma Fremgangsmaate for fremstilling av et spormerket konjugat av metallthionein og biologisk aktivt molekyl.
EP0210684A1 (en) * 1985-07-31 1987-02-04 MALLINCKRODT, INC.(a Missouri corporation) Composition comprising a radioactive metal compound for radioassaying
ATE52516T1 (de) * 1986-05-28 1990-05-15 Mallinckrodt Inc Technetiumchelate fuer die bestimmung der nierenfunktion.
DE3728599A1 (de) * 1986-12-10 1988-06-23 Hoechst Ag Verfahren zur herstellung einer mit technetium-99m-markierten organspezifischen substanz
EP0354923B1 (en) * 1987-04-02 1994-06-29 Centocor, Inc. Method for labelling antibodies with a metal ion
US5128119A (en) * 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
AU628357B2 (en) * 1988-05-02 1992-09-17 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US4917878A (en) * 1988-05-02 1990-04-17 Thomas Jefferson University Novel use of a radiolabelled antibody against stage specific embryonic antigen for the detection of occult abscesses in mammals
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
NZ314680A (en) * 1989-05-09 2000-08-25 Ortho Pharma Corp Treating localised infection or inflammation with a therapeutically conjugated chemotactic peptide
GB8914020D0 (en) * 1989-06-19 1989-08-09 Antisoma Ltd Synthetic peptides for use in thrombus detection
EP0436005B1 (en) * 1989-07-20 1995-03-29 Sandoz Ltd. Labeled polypeptide derivatives
JP3070763B2 (ja) * 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5277892A (en) * 1990-08-08 1994-01-11 Rhomed Incorporated In vivo lymphocyte tagging
ATE188387T1 (de) * 1991-02-08 2000-01-15 Diatide Inc Technetium-99m markierte polypeptide zur bildformung

Also Published As

Publication number Publication date
CA2127284C (en) 2002-02-05
ATE197767T1 (de) 2000-12-15
DE69231586D1 (de) 2001-01-04
EP0629133A4 (en) 1995-02-01
WO1993012819A1 (en) 1993-07-08
AU683833B2 (en) 1997-11-27
CA2127284A1 (en) 1993-07-08
EP0629133B1 (en) 2000-11-29
DE69231586T2 (de) 2001-07-19
AU3427293A (en) 1993-07-28
EP0629133A1 (en) 1994-12-21
DK0629133T3 (da) 2001-04-02

Similar Documents

Publication Publication Date Title
ES2155447T3 (es) Aplicaciones farmaceuticas de peptidos-iones metalicos.
EA199700239A1 (ru) Ингибиторы тромбина, основанные на аминокислотной последовательности гирудина
NL300168I2 (nl) Tweewaardige metaalzouten van 2-N,N-di(cararboxymethyl)amino-3-cyaan-4-carboxymethyl-5-thiofeencarbonzuur, werkwijze voor de bereiding ervan en deze bevattende farmaceutische preparaten.
ATE172879T1 (de) Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
DE69635959D1 (de) Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme
ES2177789T3 (es) Peptidos antagonistas de lhrh.
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
DE60024092D1 (de) Citrullin-enthaltende fibrin-derivate und ihre verwendung zur diagnose und behandlung von rheumatischer arthritis
ES2182054T3 (es) Derivados de oxazol, su produccion y uso.
SE8901552D0 (sv) Acid addition salts of amidated or glycine, their preparation and use
DE69012901T2 (de) Hämoregulierende Peptide.
KR930002373A (ko) 헥사펩티드
KR960000921A (ko) 칼시토닌 유도체 및 그 용도
ES2057572T3 (es) Agentes de reconocimiento.
EA199900755A1 (ru) Производное хинолин-2-карбоновой кислоты и его применение в качестве антагониста возбуждающих аминокислот
BR0308095A (pt) Teste para anticorpos anti-ingap
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
BR9608147A (pt) Método para descontaminação microbiana de plaquetas sanguìneas.
RU95105249A (ru) Гидрохлорид ng монометил-l-аргинина, способы его получения, способ получения фармацевтического препарата и способ лечения
DE69113437T2 (de) Therapeutische Mittel für diabetisches Gangrän.
EA199600048A3 (ru) N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции
SE8506094D0 (sv) New antibacterial agents and intermediates therefor
KR950023647A (ko) 생물학적 활성을 나타내는 폴리펩티드
BR9101544A (pt) Processo de preparacao de uma composicao contendo hexetidina ou seus derivados ou sais e sua utilizacao

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 629133

Country of ref document: ES